全球首个胃癌围术期免化疗方案!H药获中国药监局突破性疗法认定 | 新闻稿

研发客
Nov 21

首个获CDE突破性疗法认定的胃癌围手术期治疗药物,有望加速惠及胃癌患者。全球首个在胃癌围手术期以免疫单药取代术后辅助化疗的方案,其III期研究达到主要终点,显著降低复发风险,提升治愈机会。全球范围内尚无免疫疗法获批胃癌围手术期适应症,H药有望填补该领域治疗空白。2025年11月20日,复宏汉霖(2696.HK)宣布,创新型PD-1抑制剂H药 汉斯状®(斯鲁利单抗,欧洲商品名:Hetronifly®...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10